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depression using the Montgomery-Åsberg Depression Rating
Scale (MADRS). Baseline characteristics were compared to
reveal potential confounders, and adjusted mean HRQL change
from baseline were compared using analysis of covariance.
RESULTS: A total of 288 RCT patients and 244 patients from
the observational study were compared. At baseline, patients
from the observational study were statistically signiﬁcantly
younger (44.0 ± 14.5 vs. 48.0 ± 14.0, p = 0.002) and more
severely impaired (MADRS: 33.0 ± 7.4 vs. 28.9 ± 5.2, p < 0.001)
than RCT patients. Baseline EuroQoL scores were signiﬁcantly
higher for RCT patients (0.50 ± 0.28 vs. 0.30 ± 0.25, p < 0.001),
indicating a better HRQL, while QLDS scores were not signiﬁ-
cantly different (18.0 ± 4.4 vs. 17.9 ± 5.4, p = 0.69). Both
adjusted mean HRQL change from baseline scores were signiﬁ-
cantly lower for RCT patients than for patients from the obser-
vational study: -5.8 ± 0.3 vs. -7.6 ± 0.3, p < 0.001 and 0.31 ±
0.11 vs. 0.38 ± 0.09, p < 0.05 for QLDS and EuroQoL, respec-
tively. CONCLUSIONS: Improvement in HRQL scores during
acute treatment of MDD seems to indicate that their results may
be underestimated in RCT’s.
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OBJECTIVES: Estimate incidence, prevalence and pattern of
care in sickness fund insured patients with ADHD symptoms in
The Netherlands. METHODS: Claims data on approximately 6
million sickness fund insured persons during 1999–2001.
Patients on (chronic) methylphenidate (n@13,000) treatment
were assumed having ADHD symptoms. Both incident and
prevalent patients were identiﬁed and analysed. RESULTS:
Overall, ADHD prevalence and incidence was 0.24% and 0.07%
respectively. The overall male/female ADHD prevalence ratio
(%) was 0.43 :0.08. The highest prevalence and incidence ﬁgures
were seen in the 10–14 year age category with 1.8% and 0.35%
respectively. In 2000 the mean number of days of therapy were
165 days (75th percentile; 240). Average number of prescriptions
for prevalent and incident patients were 6 and 4. Of the
methylphenidate prescriptions 46% belong to the GP, 9% to a
paediatrician and 6% to a psychiatrist. For both the family
doctor and specialist together this was 23%. In children/adoles-
cents and adults (>20 years) the GP prescribes 42% and 43%
respectively. For paediatricians and psychiatrist these ﬁgures
were 14% and 4%. The most prescribed co-medication (ATC2)
for children, adolescents a) and adults b) were; J01 a) 8.8%, b)
3.5%; N02 a) 2.7%, b) 3.9%; N05 a) 11.6%, b) 26.4%; N06
a) 3.4%, b) 17.3%; R03 a) 8.4% b) 3.8%; R06 a) 4.8%, b) 2%
(ﬁgures as an average 1999–2001). Twelve percent (12%) of chil-
dren aged 10–14 received an RO3 preparation. CONCLU-
SIONS: ADHD is a common disorder. Highest prevalence was
seen in the 10–14 year age category. In general, ADHD patients
are slightly compliant with methylphenidate drug treatment.
Overall the family doctor plays an important role in the treat-
ment of ADHD. Both psycholeptics and psychoanaleptica are
commonly used as (co-) medications, especially in adults. A high
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OBJECTIVES: To present preliminary baseline data on the treat-
ment of Attention-Deﬁcit/Hyperactivity Disorder (ADHD)
symptoms and on observed co-morbid problems in German
patients enrolled in the ADORE study (Attention Deﬁcit Hyper-
activity Observational Research in Europe). METHODS:
ADORE is an ongoing 24 month, pan-European, prospective,
observational study to describe the relationship between treat-
ment regimen prescribed and quality of life in ADHD. Only
patients not formally diagnosed with ADHD previously were
included. RESULTS: A total of 392 patients with a mean age of
8.7 (SD 2.1) years with inattentive/impulsive/hyperactive symp-
toms were enrolled, of which 300 (77%) were male. ADHD
symptoms were ﬁrst observed at a mean age of 5.0 (SD 2.5)
years, while treatment was ﬁrst sought at a mean age of 7.1 (SD
2.3) years. A total of 384 subjects (98%) were formally diag-
nosed with ADHD at baseline for the ﬁrst time—the vast major-
ity according to DSM IV or ICD 10 criteria. The mean baseline
score on the ADHD Rating Scale-IV was 33.0 (SD 9.0). The
mean Clinical Global Impression-Severity score was 4.4 (SD 0.9).
The most commonly reported comorbid psychiatric symptoms
were related to: oppositional deﬁant (N = 271 (69%)) and
conduct (N = 240 (61%)) disorders, anxiety (N = 108 (28%))
and learning disorders (N = 243 (62%)). Investigators prescribed
pharmacotherapy in 78 cases (20%), some form of psychother-
apy in 66 cases (17%), and a combination of pharmacotherapy
and psychotherapy in 84 cases (21%). Short-acting
methylpenidate was prescribed for 159 (95%) out of 162
patients (41%) receiving pharmacotherapy. Psychoeducation/
counselling was prescribed for 156 (40%) and cognitive behav-
ior therapy for 44 (28%) of the patients/families. CONCLU-
SIONS: Baseline data showed: 1) an average gap of two years
between ﬁrst symptoms and seeking treatment; 2) frequent
comorbid problems; and 3) prescription of some form of treat-
ment in approximately two thirds of patients.
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OBJECTIVES: To examine the effects of initial ziprasidone dose
on discontinuation rates, using PharMetrics integrated medical
and pharmacy claims data. METHODS: Patients ≥18 years with
a diagnosis of schizophrenia and a ziprasidone claim between
March, 2001 and February, 2003, and continuously enrolled for
≥6 months before and ≥3 months after initiation of ziprasidone,
were stratiﬁed by initial daily dose (≥40 to <80mg [Low] vs. ≥80
to <120mg [Medium] vs. 120–160mg [High]). The 6-month risk
of discontinuation was examined using Cox proportional
hazards models controlling for gender, psychiatric comorbidities,
and pre-ziprasidone utilization of antipsychotics (atypical, con-
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ventional, none). RESULTS: Mean age of the sample (N = 1058)
was 38 years; 42% were male. The 6-month risk of discontinu-
ation was signiﬁcantly greater in patients with a Low vs. a High
initial dose (HR 0.74; 95% CI 0.58–0.94; P = 0.012) and trended
toward signiﬁcance when comparing a Medium vs. a High initial
dose (HR 0.86; 95% CI 0.69–1.10; P = NS). The largest differ-
ence in discontinuation rates between dose groups occurred after
the ﬁrst prescription. CONCLUSIONS: Patients initiating
ziprasidone therapy with an initial dose of at least 120mg/day
demonstrated better medication adherence compared with those
initiating at lower doses. This ﬁnding may reﬂect improved efﬁ-
cacy at daily doses ≥120mg.
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OBJECTIVES: To examine utilization of Emergency Depart-
ments (ED) for schizophrenia-related problems during a 1-year
period. METHODS: Data from 2001 and 2002 statewide 
Massachusetts ED and hospital databases were examined for
cases with a principal diagnosis of schizophrenia (ICD-9:
295.00–295.95). Cases where injury or non-related medical con-
ditions were coded were excluded. Data were examined for
demographics, visit status, arrival time, duration, disposition,
cost and repeat visits. Patients admitted were tracked by identi-
ﬁers in the hospital database. Cost estimates include accommo-
dations, ancillary and physician services, were adjusted for
national values and using 0.61 cost-to-charge ratio reported in
2004 in US$. RESULTS: Of 5686 cases identiﬁed, 72% were
male. Mean age was 46 years (range: 9–90). Visits were distrib-
uted evenly Monday through Friday, but decreased on weekends.
Almost half (48%) of all visits occurred between 3:00–11:00
PM. Visitation was coded as emergency for 57% of cases. Most
(46%) were admitted to acute hospitals, 22% transferred to
other facilities, 31% were treated and released from ED, 1% died
in ED or left AMA. Mean duration of ED visit was 5.3 hours
(median: 4.1). Mean cost per ED visit was $573 (median: $480)
for those released or transferred, and $366 for those admitted
(median: $329). In 2002, 45% of schizophrenia cases discharged
from Massachusetts acute hospitals came through ED. In one
year, 28% of those visiting an ED for a schizophrenia-related
problem had at least one other schizophrenia-related ED visit
(mean revisits: 2.1; range 1–22). Cumulative 1—year ED cost for
schizophrenia-related cases was roughly $2.6 million. CON-
CLUSIONS: The ED is a front line for schizophrenia manage-
ment, as it provides evaluation and referral services for
non-emergent patients, as well as acute treatment. Further
research is needed to determine if lack of availability, or access
to other mental health services prompted ED use.
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OBJECTIVES: To investigate utilization and persistence in
Zoloft patients versus those on other antidepressants.
METHODS: Using a 20% sample of California Medicaid claims
data from 1999 to 2003, patients on antidepressants were iden-
tiﬁed and tracked for 12 months from the ﬁrst ﬁll date of an anti-
depressant medication. Utilization patterns (discontinuation,
gap, switch, and augmentation events), medication possession
ratio (MPR), days covered (DC), and persistency (proportion of
patients on initial medication at least 80% of the time) were ana-
lyzed. Differences were tested using normal approximation with
a 2-sample test. Odds ratios were computed with respect to
Zoloft and tested using logistic regression models with propen-
sity scores. RESULTS: A total of 1403 patients were initiated on
Celexa, 1309 on Effexor, 10,758 on Paxil, 4631 on Prozac, and
2429 on Zoloft. Proportionally, more Zoloft patients were event-
free than Effexor or Paxil patients (p < 0.05), but less so than
Celexa. Adjusted odds ratios suggest that patients initiated on
Zoloft were more likely to persist with their medication than
patients on Effexor, Paxil or Prozac (OR = 0.824, 0.732, 0.762,
respectively; p < 0.05). Differences between Zoloft and Celexa
(OR = 1.040) were not statistically signiﬁcant. Zoloft had a
higher average MPR than Effexor, Paxil or Prozac, but slightly
lower than Celexa (p = 0.0259). All cohorts experienced a
decline in days covered (DC) on Day 31, 61, 91, and 181. At the
end of follow-up, 29.6% of patients initiated on Zoloft were still
taking the medication, which was signiﬁcantly higher than
patients on Effexor (24.3%), Paxil (24.9%) or Prozac (23.7%),
but slightly lower than patients on Celexa (32.6%, p = 0.0502).
CONCLUSIONS: Patients initiated on SSRI’s continue to have
relatively fast declines in medication adherence and persistence
within the recommended timeline for therapy.
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OBJECTIVES: 1) To characterize the design of drug beneﬁts of
SSRI antidepressants in health plans offered by employers in the
United States, and 2) determine the effect of raising co-payments
on compliance rates of SSRI antidepressants. METHODS: Data
comprised beneﬁt information and claims from Medstat’s Mar-
ketScan database for 2000–2003. Beneﬁt information was com-
piled from approximately 135 different plans. Any patient who
ﬁlled a prescription for an SSRI antidepressant in 2000 and was
continuously enrolled through 2001 was identiﬁed. A difference
in difference approach was used to examine the change in the
days supplied and number of claims ﬁlled for an employer that
raised their 3 tiered co-payments as compared to an employer
that kept constant one tier co-payment rates. RESULTS: Three
tier copayment structures were increasingly common among
employers. Most SSRI’s fall in tier 2 although some of the newer
SSRI’s are commonly found in tier 3. The average co-payment
for tier 1 increased from $5.40 to $7.40. The average co-
payment for tier 2 increased from $13.60 to $16.80. The average
co-payment for tier 3 increased from $25.40 to $31.20. When
the study employer raised their copayments by 50%, they expe-
rienced a 25% decline in the number of prescriptions per person
ﬁlled (from 5.2 to 3.9 prescriptions) from 2000 to 2001, while
the control employer demonstrated a 20% decline (from 6.0 to
4.8) in the number of prescriptions ﬁlled. Days supplied fell by
41.3 days or 24% in the employer that raised copayments and
by 36.3 days or 17% in the control employer. CONCLUSIONS:
Beneﬁt structure and co-payments have trended towards 3-tier
plans with increasing co-payments. As such, increasing co-
payments may have a negative effect on compliance and possi-
bly outcomes.
